Nurix Therapeutics, Inc. Stock Price, News & Analysis

Nurix Therapeutics announced positive clinical data for bexobrutideg (NX-5948) in treating relapsed/refractory CLL and WM patients. The Phase 1a/b trial showed impressive results with an 80.9% overall response rate in CLL patients and 84.2% in WM patients. The drug demonstrated durable responses, including a complete response in one CLL patient after two years of treatment. The study included heavily pretreated patients with a median of four prior therapies for CLL and three for WM. Bexobrutideg was well-tolerated across all doses, with no new safety concerns and notably no new onset atrial fibrillation. The company plans to initiate pivotal trials in 2025, positioning bexobrutideg as a potential breakthrough treatment for patients with limited therapeutic options.

Nurix Therapeutics (NRIX) announced a webcast conference call scheduled for June 12, 2025, at 8:00 a.m. ET to discuss new data from their ongoing Phase 1 clinical trial of bexobrutideg (NX-5948). The data will be presented at the European Hematology Association Congress in Milan. Two poster presentations will showcase the drug's performance: one focusing on its efficacy in relapsed refractory CLL, presented by Dr. Talha Munir, and another highlighting its clinical activity and safety in Waldenström macroglobulinemia patients, presented by Dr. Dima El-Sharkawi. The webcast will be accessible through Nurix's website, with dial-in options available for U.S. and international participants. A replay will be archived for approximately 30 days after the event.

Nurix Therapeutics (NRIX) announced that Sanofi has exercised its option to exclusively license Nurix's STAT6 program, including NX-3911, an oral STAT6 degrader. The license extension triggers a $15M payment to Nurix, bringing total collaboration payments to $127M. Nurix remains eligible for up to $465M in additional milestones plus royalties and retains U.S. co-development/co-promotion rights. NX-3911, developed using Nurix's DEL-AI platform, targets STAT6, a key factor in type 2 inflammation driving conditions like atopic dermatitis and asthma. The drug has shown promising preclinical results, achieving complete STAT6 degradation and demonstrating efficacy comparable to STAT6 gene knockout in animal models. This marks Sanofi's second license extension of a Nurix autoimmune program in 90 days, validating Nurix's drug discovery platform.

Nurix Therapeutics (NASDAQ: NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's CEO, Dr. Arthur T. Sands, and CFO, Hans van Houte, will engage in a fireside chat on June 4, 2025, at 3:45 p.m. ET in New York. The presentation will be available through a live webcast on Nurix's website, with the recording remaining accessible for 30 days following the event.

Nurix Therapeutics (NRIX) has granted inducement awards to 13 new employees on May 13, 2025, as part of their 2024 Equity Inducement Plan. The awards include stock options to purchase 87,950 shares of common stock at $9.73 per share and restricted stock unit awards (RSUs) for 60,050 shares.

The stock options will vest over 4 years, with 25% vesting after one year and the remainder vesting monthly. The RSUs will also vest over 4 years, with 25% vesting after one year and the remainder vesting quarterly. Both awards are subject to continued employment.

Nurix Therapeutics (NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, announced its participation in the upcoming RBC Capital Markets Global Healthcare Conference. The company's Chief Financial Officer Hans van Houte and Chief Business Officer Jason Kantor, Ph.D., will engage in a fireside chat on Wednesday, May 21, 2025, at 2:05 p.m. ET in New York, NY. The presentation will be available through a live webcast on Nurix's website in the Investors section, with the recording remaining accessible for 30 days following the event.

Nurix Therapeutics (NRIX) announced upcoming presentations of clinical data for their drug bexobrutideg (NX-5948) at two major scientific conferences in June 2025. The data comes from ongoing Phase 1a/b clinical trials studying the drug's effects on patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia.

The presentations will take place at the European Hematology Association Congress (EHA 2025) in Milan and the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano. The data will be featured in two posters at EHA 2025 and in both an oral presentation and poster at 18-ICML, focusing on bexobrutideg's clinical responses and safety profile as a novel Bruton's tyrosine kinase (BTK) degrader.

Nurix Therapeutics unveiled groundbreaking data at the AACR 2025 Annual Meeting showcasing their innovative DEL-AI platform, which combines DNA-encoded libraries with machine learning to accelerate drug discovery.

The company's DEL Foundation Model, developed in collaboration with Loka and supported by Amazon Web Services, demonstrates remarkable capabilities in:

• Accurately predicting novel drug binders for therapeutic targets
• Working with as little as 50% amino acid sequence similarity
• Identifying potential treatments for previously "undruggable" targets
• Inferring binders from chemical space outside training data

This AI-powered platform represents a significant advancement in drug discovery, potentially streamlining the identification of small molecule drugs, protein degraders, and molecular glues. The technology leverages Nurix's extensive database of over five billion unique DEL compounds screened against hundreds of disease targets and E3 ligase proteins.

The presentation, titled "DEL-AI: Proteome-wide in silico screening of multi-billion compound libraries using machine learning foundation models," validates the platform's ability to perform virtual DEL experiments and accurately predict experimental results.

Nurix Therapeutics (NRIX) presented positive preclinical data at AACR 2025 for multiple orally available, brain-penetrant protein degraders targeting three oncology targets. Bexobrutideg, their lead BTK degrader, demonstrated exceptional efficiency by degrading approximately 10,000 BTK copies per hour at clinically relevant concentrations.

The company showcased NRX-0305, a BRAF degrader effective across all three BRAF mutation classes while sparing healthy cells. It showed superior anti-tumor efficacy in resistant tumors compared to competitor CFT1946 and demonstrated effectiveness in combination with MEKi.

Additionally, Nurix presented data on NRX-4972, an orally bioavailable Aurora A kinase degrader developed in collaboration with Alex's Lemonade Stand Foundation. This degrader showed significant efficacy in neuroblastoma models, inducing DNA damage, apoptosis, and G2/M arrest more effectively than traditional inhibitors.